Enanta Pharmaceuticals (ENTA) Cash & Current Investments (2016 - 2025)
Historic Cash & Current Investments for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q3 2025 value amounting to $188.9 million.
- Enanta Pharmaceuticals' Cash & Current Investments fell 2390.22% to $188.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $188.9 million, marking a year-over-year decrease of 2390.22%. This contributed to the annual value of $188.9 million for FY2025, which is 2390.22% down from last year.
- Latest data reveals that Enanta Pharmaceuticals reported Cash & Current Investments of $188.9 million as of Q3 2025, which was down 2390.22% from $204.1 million recorded in Q2 2025.
- In the past 5 years, Enanta Pharmaceuticals' Cash & Current Investments registered a high of $386.6 million during Q2 2023, and its lowest value of $188.9 million during Q3 2025.
- Its 5-year average for Cash & Current Investments is $264.1 million, with a median of $249.2 million in 2022.
- In the last 5 years, Enanta Pharmaceuticals' Cash & Current Investments skyrocketed by 5720.19% in 2023 and then tumbled by 4048.27% in 2024.
- Quarter analysis of 5 years shows Enanta Pharmaceuticals' Cash & Current Investments stood at $259.1 million in 2021, then dropped by 17.21% to $214.5 million in 2022, then skyrocketed by 57.2% to $337.2 million in 2023, then crashed by 35.73% to $216.7 million in 2024, then decreased by 12.84% to $188.9 million in 2025.
- Its Cash & Current Investments stands at $188.9 million for Q3 2025, versus $204.1 million for Q2 2025 and $193.4 million for Q1 2025.